Rhumbline Advisers Raises Stock Position in ZimVie Inc. (NASDAQ:ZIMV)

Rhumbline Advisers raised its holdings in ZimVie Inc. (NASDAQ:ZIMV) by 3.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 45,214 shares of the company’s stock after purchasing an additional 1,303 shares during the quarter. Rhumbline Advisers owned 0.16% of ZimVie worth $631,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. boosted its stake in shares of ZimVie by 66.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 183,419 shares of the company’s stock worth $2,911,000 after acquiring an additional 73,395 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new position in ZimVie during the third quarter worth approximately $891,000. Barclays PLC grew its holdings in ZimVie by 338.4% in the third quarter. Barclays PLC now owns 43,437 shares of the company’s stock valued at $690,000 after purchasing an additional 33,529 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of ZimVie in the third quarter valued at approximately $528,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of ZimVie in the third quarter valued at approximately $470,000. 95.63% of the stock is owned by institutional investors and hedge funds.

ZimVie Trading Down 2.0 %

ZIMV opened at $12.55 on Friday. The firm has a market capitalization of $347.35 million, a price-to-earnings ratio of -0.96 and a beta of 2.10. The company’s 50 day simple moving average is $13.70 and its two-hundred day simple moving average is $14.64. ZimVie Inc. has a 1-year low of $12.25 and a 1-year high of $22.40. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.94 and a quick ratio of 1.38.

ZimVie (NASDAQ:ZIMV) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. The firm had revenue of $111.52 million for the quarter, compared to the consensus estimate of $113.67 million. ZimVie had a positive return on equity of 2.90% and a negative net margin of 77.31%. Analysts expect that ZimVie Inc. will post 0.6 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of ZimVie in a report on Thursday, February 27th.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.